Lineage Cell Therapeutics (LCTX) Net Margin (2016 - 2025)
Historic Net Margin for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to 92.91%.
- Lineage Cell Therapeutics' Net Margin fell 135000.0% to 92.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 296.07%, marking a year-over-year decrease of 661600.0%. This contributed to the annual value of 195.62% for FY2024, which is 445000.0% up from last year.
- Per Lineage Cell Therapeutics' latest filing, its Net Margin stood at 92.91% for Q3 2025, which was down 135000.0% from 698.95% recorded in Q2 2025.
- Over the past 5 years, Lineage Cell Therapeutics' Net Margin peaked at 56.02% during Q4 2021, and registered a low of 969.73% during Q2 2021.
- Its 5-year average for Net Margin is 313.58%, with a median of 225.77% in 2023.
- Per our database at Business Quant, Lineage Cell Therapeutics' Net Margin soared by 12693600bps in 2021 and then plummeted by -3704800bps in 2023.
- Quarter analysis of 5 years shows Lineage Cell Therapeutics' Net Margin stood at 56.02% in 2021, then crashed by -493bps to 332.22% in 2022, then skyrocketed by 32bps to 225.77% in 2023, then skyrocketed by 50bps to 113.32% in 2024, then rose by 18bps to 92.91% in 2025.
- Its Net Margin stands at 92.91% for Q3 2025, versus 698.95% for Q2 2025 and 401.26% for Q1 2025.